主题重点

选择性的设计、筛选、评估

变构激酶抑制剂的特定与分析

共享结合阻碍

中枢神经系适应的激酶：大课题

炎症与自体免疫—主要计画

癌的激酶—PI3、mTOR、cMet等

追求新的激酶标的

DMPK、Tox的筛选与监测

计算机手法的进化

抵抗性—将来的课题

Click here for the preliminary agenda

著名的学术相关人员

Mark Ashwell, ArQule Inc

Peter Brandt, Beactica AB

Dirksen Bussiere, Novartis Vaccines & Diagnostics Inc.

Jean Cui, Pfizer, Inc.

Greg Cuny, Brigham & Women’s Hospital

David C. Dalgarno, ARIAD Pharmaceuticals Inc.

David H. Drewry, GlaxoSmithKline

Isabelle Dussault, Amgen

Doriano M. Fabbro, Novartis Institutes for BioMedical Research

Daniel Goldberg, Boehringer-Ingelheim Pharmaceuticals

Andrew C. Good, Genzyme Corp

John D. Haley, OSI Pharmaceuticals

Ronald Knegtel, Vertex Pharmaceuticals (Europe) Ltd.

Ravi G. Kurumbail, Pfizer, Inc.

Chris Liang, Xcovery, LLC

Carol MacKintosh, University of Dundee

Yibing Shan, D. E. Shaw Research

Juswinder Singh, Avila Therapeutics, Inc.

Rajinder Singh, Rigel Pharmaceuticals Inc.

Eli Wallace, Array BioPharma

Neil Wishart, Abbott

Paul Yu, Massachusetts General Hospital